Vnitřní lékařství 1/2025

PŘEHLEDOVÉ ČLÁNKY Estrogenní léčba a činnost jater | 39 / Vnitř Lék. 2025;71(1):37-39 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz LITERATURA 1. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005 Sep 28;227(2):115-24. doi: 10.1016/j.canlet.2004. 10. 007. Epub 2004 Nov 19. PMID: 16112414. 2. Lee AJ, Cai MX, Thomas PE, et al. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98. doi: 10.1210/en.2003-0192. PMID: 12865317. 3. Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17alpha- -ethinylestradiol: a new look at an old drug. Clin Pharmacokinet. 2007;46(2):133-57. doi: 10.2165/00003088-200746020-00003. PMID: 17253885. 4. Rodrigues AD. Drug Interactions Involving 17α-Ethinylestradiol: Considerations Beyond Cytochrome P450 3 A Induction and Inhibition. Clin Pharmacol Ther. 2022 Jun;111(6):12121221. doi: 10.1002/cpt.2383. Epub 2021 Aug 24. PMID: 34342002. 5. Rose DP, Goldman M, Connolly JM, Strong LE. High-fiber diet reduces serum estrogen concentrations in premenopausal women. Am J Clin Nutr. 1991 Sep;54(3):520-5. doi: 10.1093/ajcn/54. 3. 520. PMID: 1652197. 6. Harrington WR, Sengupta S, Katzenellenbogen BS. Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells. Endocrinology. 2006 Aug;147(8):3843-50. doi: 10.1210/en.2006-0358. Epub 2006 May 11. PMID: 16690804. 7. Rodrigues AD. Drug Interactions Involving 17α-Ethinylestradiol: Considerations Beyond Cytochrome P450 3A Induction and Inhibition. Clin Pharmacol Ther. 2022 Jun;111(6):12121221. doi: 10.1002/cpt.2383. Epub 2021 Aug 24. PMID: 34342002. 8. Raps M, Helmerhorst F, Fleischer K, et al. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. J. Thromb. Haemost. 2012;10:992997. doi: 10.1111/j.1538-7836.2012.04720.x. 9. Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet. Gynecol. Scand. 2002;81:482-490. doi: 10.1034/j.1600-0412.2002.810603.x. 10. Mawet M, Maillard C, Klipping C, et al. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. Eur. J. Contracept. Reprod. Health Care. 2015;20:463-475. doi: 10.3109/13625187.2015.1068934. 11. Klipping C, Duijkers I, Mawet M, et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021;103:213-221. doi: 10.1016/j.contraception.2021. 01. 001. 12. Kluft C, Zimmerman Y, Mawet M, et al. Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol. Contraception. 2017;95:140147. doi: 10.1016/j.contraception.2016. 08. 018. 13. Douxfils J, Klipping C, Duijkers I, et al. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. Contraception. 2020;102:396-402. doi: 10.1016/j.contraception.2020. 08. 015. 14. Arnal JF, Scarabin PY, Trémollières F, et al. Estrogens in vascular biology and disease: Where do we stand today? Curr. Opin. Lipidol. 2007;18:554-560. doi: 10.1097/MOL.0b013e3282ef3bca. 15. Hodgin JB, Krege JH, Reddick RL, et al. Estrogen receptor α is a major mediator of 17β-estradiol’s atheroprotective effects on lesion size in Apoe–/– mice. J. Clin. Investig. 2001;107:333340. doi: 10.1172/JCI11320. 16. Coelingh Bennink HJT, Verhoeven C, Zimmerman Y, et al. Pharmacodynamic effects of the fetal estrogen estetrol in postmenopausal women: Results from a multiple-rising-dose study. Menopause. 2017;24:677-685. doi: 10.1097/GME.0000000000000823.

RkJQdWJsaXNoZXIy NDA4Mjc=